1 / 55

Goiter: Pathophysiology and clinical aspects

Explore the pathophysiology and clinical aspects of goiter, including iodine intake, genetic factors, and related conditions like Cretinism and Thyroid Hormone Synthesis. Learn about goiter development, mutations, treatment, and more.

danat
Download Presentation

Goiter: Pathophysiology and clinical aspects

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Goiter: Pathophysiology and clinical aspects Joaquín Lado Abeal, MD, PhD Department of Internal Medicine TTUHSC-SOM, Lubbock

  2. Iodine intake (goitrogens) Gender Genetic

  3. From Iodine Satus Worldwide. WHO Global Data Base on Iodine Deficiency. 2004

  4. From Iodine Satus Worldwide. WHO Global Data Base on Iodine Deficiency. 2004

  5. San Bartolomeu da Mota (A Mota, Arzua, Galicia)

  6. Dr Gregorio Maranon

  7. CRETINISM Myxedematose Neurological

  8. TSH Hyperthyrodism Hypothyrodism T4 T3 High T4/T3 Low TSH Low T4/T3 High TSH

  9. Thyroid Hormone Synthesis

  10. Insulin/IGF-I TSH Diferentiation Proliferation

  11. Pituitary TSHoma TSH

  12. Graves-Basedow disease

  13. TSHR mutations

  14. 0 100 200 300 400 500 600 51 49 47 45 250 15 200 150 10 100 5 50 0 0 250 200 150 0 100 200 300 400 500 600 Syndrome of Resistance to Thyroid Hormone Action (SRTH) 37 36 Neck diameter (cm) 35 34 Weight (Kg) 33 32 31 30 November 2001 2 1 0.5 TSH (mU/L) (µg/L) TT4 (µg/dl) TG 0.1 0. 05 L-T dose 3 µg c.2.d. Number of days May 2003

  15. TSH (µU/ml) MA Pisarev, RD Utiger, JP Salvaneschi, N Altschuler, LJ DeGroot. Serum TSH and thyroxine in Goitrous Subjects in Argentina. J Clin Endocr. 30:680-681. 1970.

  16. MULTINODULAR GOITER 28.1.04 30.8.05 NORMAL 11.4.05 TSH µU/ml 0.08 0.35-5.50 0.42 0.10 1.08 FT4 ng/dl 0.88 0.80 0.85-1.86 3.65 3.29 3.89 2.20-4.70 FT3 pg/ml Ab TPO < 33 AbTG < 100

  17. Pendred Sydrome

  18. Total Thyroidectomy (February 05) 50 µg/day T4 (starting March 04) 100 µg/day T4 Post surgery (starting February 05) 100 µg/day T4 (starting Nov 04)

  19. rT3 D3 T3 MCT8 T4 T4 T3 D1, D2 T4

  20. T wildtype GTAAGTTCATTG mutant TAAGTTCATTG c.886C>T p.R277X c.6205+1delG Exon 35 skipping THYROGLOBULIN GENE MUTATIONS Red=goiter R277X c.6205+1delG WT/ c.6205+1delG WT/ c.6205+1delG WT/ c.6205+1delG WT / WT WT/ p.R277X p.R277X / c.6205+1delG p.R277X / c.6205+1delG p.R277X / c.6205+1delG p.R277X / c.6205+1delG T Intron 35 Exon 35 Exon 7

  21. Exon 35 skipping TT GCT CAA AAT AAT GCT CCC AGT TTT TGC CCT TTG GTT GTT CTG CCT TCC CTC ACA GAG AAG I A Q N N A P S F C P L V V L P S L T E K K P M S L Exon 36 Exon 34

  22. WT /c.6205+1delG p.R277X /c.6205+1delG

  23. Thyroglobulin mutations unfolded protein response apoptosis defective hormone synthesis p53, NF-kB, MPAKs, VEGF high serum TSH Goiter oxidative stress BRAF mutations Cancer

  24. Afrikaner cow 9 TG 48 1

  25. RAS INACTIVE Pi GEF GDP GTP GAP GTP GDP ACTIVE

  26. PLC DAG PKC R Wetzker, Frank-D Bohmer. Transactivation joins multiple tracks to the ERK/MAPK Cascade. Nature Reviews. Molecular Biology. 4: 651-657. 2003.

  27. GTP RAS RalGDS Raf PLC PI3K MEK Ca 2+ intracelular AKT/PKB Ral ERK Growth, cell survival H2O2 H2O2 Transcription Proliferation Cell survival Proliferation

  28. RAS Mutations in Thyroid Tumors 30% Colloid nodules 25% Follicular adenomas Papilary carcinomas 20% Follicular carcinomas 15% 10% 5% 0% H1-RAS (12/13) H2-RAS (61) K1-RAS (12/13) K2-RAS (61) N1-RAS (12/13) N2-RAS (61) V. Vasko et al. JCEM. 88(6):2745-2752. 2003

  29. Normal Human Thyrocites TTF-1 PAX-8 Tg 3 Weeks 3 Weeks 4 Days CONTROL H-RAS (V-12) V Gire, D Wynford-Thomas. Oncogene. 19:737-744.2000

  30. RAS RalGEF PI3K MAPK CELL SURVIVAL PROLIFERATION GROWTH

  31. Chromosomal imbalance t(2;3)(q13;p25) & -20 15q loss AR Marques et al. JCEM. 87(8): 3947-3952. 2002

  32. PAX8-PPARG t(2;3)(q13;p25) TG Kroll et al. Science. 289:1357-1360. 2000 Placzkowski KA et al. PPAR Research. 2008

  33. A PPARg 1 (exon 1) PAX8 (exon 8) B PPARg 1 (exon 1) PAX8 (exon 10) PAX8 (exon 10) PAX8 (exon 8)

  34. Chernobyl Disaster (April 26 1986)

  35. Aneuploidy (33% Goiters) 66 XXX From T Dettori et al. Genes, Chromosomes & Cancer. 38: 22-31. 2003.

  36. M Iliszko et al. Cancer Genetic and Cytogenetcis. 161: 178-180. 2005

More Related